Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR CD22
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR CD22 is a non-viral modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of hematologic malignancies. The therapy utilizes Hauul Bio's proprietary ModCAR platform, which employs a non-viral, modular single-chain variable fragment (scFv)-fusion protein system. In this system, the scFv-fusion protein is designed to target and bind to CD22-positive malignant cells, allowing for flexible and efficient targeting of cancer cells without the need for viral transduction. ModCAR CD22 is currently in the discovery and research stage.
- Other names
- ModCAR-CD22ModCAR-CD-22ModCAR-CD 22
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on ModCAR CD22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR CD22.